IL2 and neoplasm: Although simultaneous expression of IL2 and TAA in the same rVACV construct have been studied and indicated that the efficacy of a TAA-produced anti-tumor response can be enhanced by IL2 (25–27), oncolytic rVACVs expressing IL2 and CTL epitopes from TAAs have not yet been comprehensively investigated in tumor therapy.